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Abstract
Objective—Liver transplantation is limited by ischemic injury which promotes endothelial cell 
and hepatocyte dysfunction and eventually organ failure. We sought to understand how endothelial 
state determines liver recover after hepatectomy and engraftment.
Design—Matrix-embedded endothelial cells (MEECs) with retained healthy phenotype or 
control acellular matrices were implanted in direct contact with the remaining median lobe of 
donor mice undergoing partial hepatectomy (70%), or in the interface between the remaining 
median lobe and an autograft or isograft from the left lobe in hepatectomized recipient mice. 
Hepatic vascular architecture, DNA fragmentation and apoptosis in the median lobe and grafts, 
serum markers of liver damage and phenotype of macrophage and lymphocyte subsets in the liver 
after engraftment were analyzed 7 days post-op.
Results—Healthy MEECs create a functional vascular splice in donor and recipient liver after 
70% hepatectomy in mouse protecting these livers from ischemic injury, hepatic congestion and 
inflammation. Macrophages recruited adjacent to the vascular nodes into the implants switched to 
an anti-inflammatory and regenerative profile M2. MEECs improved liver function and the rate of 
liver regeneration and prevented apoptosis in donor liver lobes, autologous grafts, and allogeneic 
engraftment.
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Conclusions—Implants with healthy endothelial cells rescue liver donor and recipient 
endothelium and parenchyma from ischemic injury after major hepatectomy and engraftment. This 
study highlights endothelial-hepatocyte crosstalk in hepatic repair and provides a promising new 
approach to improve regenerative medicine outcomes and liver transplantation.
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INTRODUCTION
Liver disease is one of the leading causes of death in the world.1 Hepatectomy and liver 
transplantation are the standard of care in patients with tumors of hepatic origin and end-
stage liver disease.2 Yet, in 2014, only 40% of eligible patients received a liver transplant, 
which translates into a shortage of about 10,000 donors per year.3 During the same period, 
23% of patients from the waiting list died and an additional 20% of patients were removed 
from that list as they became too sick to undergo surgery.3 Recent efforts have been devoted 
to generate hepatocyte-like cells and organ buds for transplantation.4–5 However those 
promising tools are still far from replacing liver transplantation in clinics. There is still much 
we do not know of the biology of liver injury and repair in these settings. Ischemic injury 
promotes a cascade of cellular responses that lead to inflammation, cell death, and ultimately 
hepatic and even multiorgan failure in recipients as well as donors.6–10 Further elucidation 
of the governing biology will help explain these events, provide potential means of avoiding 
them and perhaps even increase the number and size of successful donor grafts. Current 
therapeutic strategies focus on stimulating angiogenesis in grafts and reducing apoptosis and 
inflammation.11–12 Indeed, angiogenesis is an essential driving force for liver regeneration, 
the response to injury and organogenesis.13–14
Growing evidence suggests that liver sinusoidal endothelial cells (LSEC) are synergistic 
with hepatocyte proliferation and in establishing isograft tolerance.15–16 LSEC play critical 
protective roles controlling vascular tone, homeostasis, inflammation, and toxicant 
clearance.15 Preservation of a healthy LSEC phenotype is indispensable to minimization of 
liver injury and improvement of successful engraftment after hepatectomy and 
transplantation.17 Direct injection or transplantation of isolated healthy endothelial cells 
have been proposed to repair organ damage or replace deficient functions,18–19 but the 
immune reaction that they engender limits clinical utility.
Matrix-embedded endothelial cells (MEECs) places endothelial cells in a three-dimensional 
collagen-based scaffold that eliminates their immunogenicity in vitro and in vivo.20–21, 
stimulates Th2 lymphocyte and M2 macrophage phenotype, and exhibit a muted expression 
pattern of adhesion molecules and chemokines and a markedly decreased expression of 
major histocompatibility complex (MHC) class II molecules.22–23 We therefore proposed 
that healthy MEECs could boost the recovery of hepatocyte function by protecting host 
endothelium from inflammation and by promoting angiogenesis after hepatectomy and liver 
engraftment, and examined these effects in a murine model of hepatectomy and liver 
engraftment.
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METHODS
Cell culture and seeding of MEECs or NIH/3T3 fibroblasts
Human umbilical vein endothelial cells (HUVECs) pooled from 3 donors or HUVECs 
constitutively expressing GFP were grown in endothelial growth medium supplemented with 
EGM-2 growth supplements (Lonza). NIH/3T3 fibroblasts (CRL-1658, American Type 
Culture Collection, ATCC, Manassas, VA) were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% of fetal bovine serum. NIH/3T3 fibroblasts or HUVECs 
(passage 3–5) cultured on gelatin-coated tissue culture plates (0.1% gelatin type A, Sigma, 
St. Louis, MO) were then were seeded in 3D matrix. For cell-matrix seeding, compressed 
denatured collagen matrices (Gelfoam, Pfizer, New York, NY) were cut into 1 × 1 × 0.3 cm 
blocks and hydrated in culture medium at 37°C for 2h. Then 4.5 × 104 ECs or NIH/3T3 
fibroblasts (suspended in 50 μL media) were seeded onto one surface of the hydrated matrix 
and allowed to attach for 1.5h. Subsequently, the matrix was turned over and additional 4.5 × 
104 ECs were added to infiltrate from the second side. After an additional 1.5 h incubation 
period to enable cell attachment, each cell-seeded construct was carefully transferred to a 
separate 30 mL polypropylene tube containing 10 mL of culture medium. Matrices were 
cultured for 2 weeks, with media changed every 48h under standard culture conditions (37°C 
humidified environment with 5% CO2).
Animal model of 70% hepatectomy and liver engraftment
Male C57BL/6 mice (9–12 weeks old) were purchased from Charles River Laboratories 
(Wilmington, MA). The animals were maintained in a temperature-controlled room (22°C) 
on a 12h light-dark cycle. After arrival, mice were continuously fed ad libitum until 
euthanasia. Partial hepatectomy was performed as previously described.24 An ischemic 
stump of ~7 mm was retained in the median lobe to allow immobilization of the different 
implants (acellular, MEECs or embedded NIH/3T3 fibroblasts) and to investigate the 
splicing and bridging of vessels to the irrigated part of the median lobe (supplementary 
figure 1). The right lobe was used to assess paracrine effects. For liver engraftment, excised 
mouse left lobes from a group of ten mice were excised and maintained in warm EGM-2 
medium (37°C) until engraftment to the remaining median lobe and stump of a same or 
different group of ten mice in the presence or the absence of MEECs, or acellular matrices at 
the interface between recipient and donor liver (supplementary figure 1). Animals were 
sacrificed after one week. Mouse blood samples were collected by intracardiac puncture. 
Serum was separated by centrifugation at 3,000 × g for 10 min and was then transferred into 
polypropylene tubes and stored at −80°C until analysis. Liver restoration rate was calculated 
as liver weight/body weight × 100.
Whole-mount multiphoton imaging of macrophage presence and angiography in liver, 
gene expression analysis by Real-Time PCR, TUNEL assay, Western Blotting and “in vitro” 
studies
See on-line supplementary methods.
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Statistical analysis
Data are expressed as mean standard error. Statistical analysis of the results was performed 
by one-way analysis of variance (ANOVA), the Newman-Keuls test, and the unpaired 
Student’s t test when appropriate. Differences were considered to be significant at a p value 
of 0.05 or less.
RESULTS
MEECs rescue the ischemic median lobe in mice undergoing 70% hepatectomy
Partial hepatectomy (70%) consisted of excising most of healthy median lobe figure 1A and 
the whole left lobe. Acellular matrix or MEECs were implanted adjacent to the remaining 
ischemic portion of median liver lobe. Seven days later, the animals were sacrificed. At this 
time the macroscopic aspect of part of the residual median liver lobe from hepatectomized 
mice in the absence or the presence of acellular matrix indistinguishably displayed a 
phenotype of hepatic ischemia with a pale and stiff appearance typical in this animal model 
(figure 1B–C). Only 3 of 10 acellular implants were still attached to the liver at the time of 
sacrifice. In contrast, all implants with MEECs strongly attached to the ischemic part of the 
median liver lobe one week after implantation and the hepatic tissue macroscopically 
resembled normal liver (figure 1D). As this difference could be explained by a better blood 
perfusion of median lobes with MEECs, we analyzed the vascular structure at the interface 
between the injured liver and matrices by angiography. We observed that a new functional 
vascular network was created into the implant (supplementary figure 2) that anastomosed 
host livers (figure 1E). This network was not present in acellular matrices of denatured 
collagen (figure 1E). The newly formed vascular anastomoses were originated in part from 
the extension of hepatic vessels and in part from MEEK-generated angiogenesis as assessed 
by angiography after implanting ECs constitutively expressing GFP (supplementary figure 
3). A small number of macrophages invaded the implant and were found adjacent to vessel 
ramifications (figure 1E) promoting vascular sprouting as recently reported.25 Vessel bypass 
between dysfunctional host vessels and implanted healthy MEECs allowed a reduction of 
blood congestion of the whole median lobe through the significant decrease of the vascular 
diameter (37%, p<0.01) and preservation of functional vessels (93%, p<0.0001) as 
compared to acellular matrices or the absence of implant (figure 1F). Since MEECs have 
been reported to attract endothelial progenitor cells (EPC)26 and EPC are major contributors 
of HGF levels after hepatectomy, we quantified hepatic expression of HGF in the ischemic 
lobe after 3 and 7 days of implantation of MEECs. HGF gene expression is up-regulated in 
ischemic liver lobes early after hepatectomy but drops to basal levels soon thereafter and has 
minimal if any impact on regeneration (figure 1G). Acellular matrices do not change this 
kinetics but MEECs drove HGF 5-fold higher than in ischemic livers attached to acellular 
implants and with those different levels maintained at day 7 (figure 1G). These increased 
levels of liver HGF were in part attributed to the increase of recruitment of bone marrow 
EPCs to the liver (supplementary figure 4).
We further investigated how MEECs attracted EPCs. MEECs (HUVECs in 3D) displayed 
much higher expression of the EPC attractants HGF and stromal cell-derived factor 1 
(SDF-1) than HUVECs in standard 2D tissue-culture plates (supplementary figure 5A), and 
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induced the expression of CXCR4 and CXCR7, two receptors involved in EPC migration- 
an induction obliterated in the presence of anti-HGF antibodies (supplementary figure 5B). 
To analyze cell damage and apoptosis induced by ischemia we stained median liver lobes 
using TUNEL assay and analyzed the activation of caspase 3. DNA fragmentation and 
damage was reduced by 85%, p<0.0001 (figure 1H) and apoptosis (i.e. active caspase 3 
levels) dropped by 72%, p<0.01 (figure 1I) in livers implanted with MEECs as compared 
with livers receiving acellular implants. Therefore implants of healthy MEECs protect 
endothelium and parenchyma from death and loss of function in the ischemic lobe of liver 
donor after hepatectomy.
Beneficial effects of MEECs in vascular congestion, hepatic function, and liver 
regeneration after hepatectomy
To analyze the paracrine impact of implantation of healthy MEECs in the regenerating lobes 
we quantified vascular effects in right lobe 7 days post-op. Livers with or without acellular 
implant showed an identical increase of vascular diameter in comparison to sham livers 
(figure 2A). In contrast MEEC implants reduced vasodilation without altering angiogenesis 
in the growing organ expressed as number of new anastomoses (figure 2A). The same 
pattern was observed in the total number of macrophages in the right lobe, that is, an 
increase of the amount of macrophages after acellular implantation or without matrix and a 
drop in number of macrophages when MEECs were implanted (figure 2B). The recovery of 
the ischemic lobe by implants of MEECs resulted in an increase of 15% of total liver mass 
restoration as compared with livers with acellular matrices or without implants (figure 2C). 
This value of liver regeneration using MEECs implies complete recovery of original hepatic 
mass. As a result of the beneficial effects of MEECs, hepatic injury was reduced as seen in 
serum levels of ALT and AST (figure 2D).
MEECs switch the phenotype of macrophages and T-helper lymphocytes from pro-
inflammatory to anti-inflammatory and pro-regenerative
The reduction of the number of inflammatory cells using MEECs suggested that embedded 
ECs could have hepatic immunomodulatory effects on macrophage profile stimulating repair 
and reducing inflammation as reported.22 To identify the phenotype of macrophage subsets 
in livers after MEECs implantation we quantified the gene expression of M1 (inducible 
nitric oxide synthase: iNOS; cyclooxygenase 2: COX-2; interleukin 1β: IL1B) and M2 
(arginase 1: Arg1; mannose receptor C type 1: MRC1; resistin-like alpha 1: Retn1a) genes 
by Real-Time PCR. Expression of genes corresponding to the pro-inflammatory macrophage 
profile M1 was progressively up-regulated from day 3 to day 7 post-hepatectomy in livers 
without matrix implants and those receiving acellular matrices - up-regulation that was 
significantly prevented by implants of MEECs (figure 3A). Expression of genes 
corresponding to the anti-inflammatory and pro-regenerative profile M2 was not 
significantly up-regulated in livers without MEECs and those receiving acellular matrices 
but was increased by implants of MEECs (figure 3B). It is documented that the switch from 
M1 to M2 in macrophages is mainly promoted by IL-4 and IL-10 released by Th2 cells27 
and that Th2 subset is stimulated in T cells in contact with MEECs23. We found that hepatic 
abundance of Th1 genes progressively rose from day 3 to day 7 post-hepatectomy in 
ischemic lobe with or without acellular matrix but dropped to physiological levels in livers 
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in contact with MEECs (figure 3C). Th2-derived cytokines were only up-regulated after 
hepatectomy when MEECs were implanted (figure 3D). We also investigated whether the 
beneficial effects of embedded endothelial cells on liver damage, regeneration and 
immunomodulation is specific for endothelial cell or can be promoted by other cell types, 
for example, fibroblasts. In contrast to MEECs, implants of embedded 3T3 fibroblasts 
allowed for cell invasion into host tissue promoting increased stiffness (supplementary figure 
6A) and if anything reduced rather than improve hepatic damage (supplementary figure 6B) 
or regeneration (supplementary figure 6C) in the ischemic part of the median lobe. These 
implants also promoted a trend to a reduction in liver HGF expression that did not reach 
statistical significance (supplementary figure 6D). Moreover, again unlike endothelial cells, 
implants of 3T3 fibroblasts could not modify the profile of M1 macrophages (supplementary 
figure 6E) but did reduce significantly the subset of pro-regenerative M2 macrophages 
(supplementary figure 6G) as compared with livers implanted with acellular matrices. No 
differences were found in hepatic profiles of Th1 (supplementary figure 6G) or Th2 
lymphocytes (supplementary figure 6H) between animals implanted with 3T3 fibroblasts or 
acellular matrices.
MEECs bridge vessels from recipient and donated autografts protecting from ischemic 
injury
Injury derived from ischemia occurs in various clinical settings, such as transplantation, 
hepatectomy for cancer resection, and hemorrhagic shock11. For that reason, we 
hypothesized that healthy MEECs could help re-vascularize liver grafts to rescue 
dysfunctional endothelium in transplantation. We implanted MEECs in the interface 
between median ischemic lobe after hepatectomy and a liver graft from the left lobe of the 
same mouse (figure 4A). Either median ischemic lobe or autograft displayed a pale color 
when acellular denatured collagen was implanted (figure 4B). In contrast, both remaining 
median lobe and autograft showed a normal liver color when MEECs were implanted in 
between (figure 4C). Analyzing the vascularity, we found that blood perfusion was very 
reduced or inexistent in median lobe and autograft in contact with acellular implants. In 
contrast implanted healthy MEECs bridged vessels between remaining median lobe and 
autograft (figure 4D) and promoted EPC recruitment into the injured lobe as shown by 
increased levels of HGF (supplementary figure 3A). Consequently, MEECs preserved 
vascular functionality in median lobe and reduced vessels diameter and congestion (figure 
4E). That protection of MEECs against ischemia resulted in a drastic reduction of hepatic 
median lobe damage (supplementary figure 4A) and autograft cell injury (85% of reduction) 
(figure 4F) and apoptosis (figure 4G). Overall, mice receiving MEECs displayed 
significantly lower levels of serum transaminases indicating a reduction in hepatocyte 
damage (figure 4H).
MEECs bridge vessels from recipient and donated isografts protecting from ischemic 
injury and immunomodulating a reduction of graft rejection
MEECs attenuate immune rejection in allo- and xenogeneic cell implants.21 For this reason, 
we now analyzed the effects of these implants in hepatic isografts. Median ischemic lobe 
and isograft displayed a pale color when acellular denatured collagen was implanted and that 
ischemic color was partially reverted when MEECs were used (figure 5A and B). Vascularity 
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was significantly reduced or entirely obliterated in the median lobe and isograft in contact 
with acellular implants. In contrast, MEECs connected vessels between the median lobe and 
isograft (figure 5C) and stimulated EPC recruitment into the injured area as shown by 
enhanced levels of HGF (supplementary figure 3B). As a result, healthy MEECs protected 
the dysfunctional vascular network in median lobes and reduced congestion (figure 5D). 
These beneficial effects on ischemia were translated into a significant reduction of hepatic 
median lobe injury (supplementary figure 3B) and isograft cell death (79% of reduction) 
(figure 5E) and apoptosis (figure 5F). Although 50% of immunocompetent mice implanted 
with isografts died of acute tissue rejection within the first 24 hours, the other half that 
survived exhibited intragraft immunotolerance expressed as reduction of Th1 (INFγ and 
IL-2) and increase of Th2 (IL-4 and IL-10) cytokine expression (figure 5G). Those mice 
receiving isografts in the presence of MEECs implants showed improved levels of serum 
transaminases thus reducing hepatocyte damage (figure 5H).
DISCUSSION
Ischemic injury is a multifactorial process that affects graft function after liver 
transplantation. Although recent efforts have improved organ preservation and surgical 
outcomes28–29, there is still a need to understand the basic biology and provide further 
support of organ viability. Liver ischemia, apoptosis and endothelial dysfunction restrict the 
success of hepatectomy and liver transplantation. The recovery of blood perfusion in both 
the recipient and the graft, and protection from adverse inflammatory response are critical 
events for successful transplantation.2 M2 profile of macrophages is potentiated in response 
to partial hepatectomy or hepatic injury to regenerate the damaged tissue.30 However, 
M1/M2 balance in macrophages is flexible and the M1 inflammatory phenotype can 
perpetuate chronic hepatic inflammation and interfere with liver regeneration.31 This 
manuscript demonstrates that viability of liver sinusoidal endothelium determines the fate of 
an engrafted hepatic transplant. Implanted healthy matrix-embedded endothelial cells can 
rescue dysfunctional endothelium in an ischemic liver and stimulate the immune system to 
boost engraftment and regeneration.
Hepatic sinusoids are lined by a thin layer of functionally unique endothelial cells. LSECs 
display a high-capacity to clear colloids and soluble waste macromolecules from the 
circulation to protect hepatocytes, but as such are also the initial target of injury from 
circulating drugs and toxins and by ischemia-reperfusion injury.2 After toxic liver injury, 
partial hepatectomy or transplantation, damaged LSECs progressively become dysfunctional 
and may interfere with hepatocyte function and liver regeneration. LSEC progenitor cells 
arise from the liver and bone marrow (BM LSEC) to contribute to the regenerative response 
of hepatocytes. These mobilized BM LSEC progenitors engraft in the liver, proliferate and 
are the highest secretors of the mitogen hepatocyte growth factor (HGF).32–33 While mature 
LSECs express and secrete low levels of HGF, high levels of HGF are observed in liver 
endothelial progenitor cells and bone marrow-derived LSEC (BM LSEC) progenitors after 
liver injury.32–33 LSEC dysfunction or a failure of mobilization of BM LSEC translates into 
a defective secretion of HGF and an impaired hepatocyte proliferation.33 MEECs retain high 
capacity of attracting endothelial progenitors cells.26 Herein we describe that matrix 
embedding upregulates endothelial cell expression of two EPC-recruiting factors SDF-1 and 
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HGF34, which especially in the case of HGF stimulated the expression of the receptors 
CXCR4 and CXCR7 in BM EPCs recruiting these latter cells to the implant area and injured 
liver.34 Once recruited, EPCs in turn secrete more HGF promoting a positive feedback 
(supplementary figure 7). The mobilization of BM LSEC progenitors by MEECs to the 
injured area stimulate angiogenesis, and this recovery of endothelial cells improves 
hepatocyte survival, function and liver regeneration. Indeed, the recruitment of BM LSEC is 
essential for hepatocyte proliferation and restoration of liver mass.35 MEECs also generate a 
functional vascular network that splice injured vessels protecting livers from ischemia and 
reducing apoptosis.
Controlled inflammation is important to the integration and vascularization of biomaterial 
scaffolds.36 MEECs achieve an energy state that minimizes stress, shields their 
immunogenic surface37 and maximizes the secretion of regulatory factors promoting the 
switch of Th1 to Th223 lymphocytes, and the subsequent switch of M1 to M2 macrophages 
to enhance repair. Indeed, some factors secreted by MEECs induce formation and 
differentiation of host splenocytes into Th2, but not Th1, cytokine-producing cells.23 We 
demonstrate here that one of these regulatory factors highly up-regulated in MEECs is HGF. 
A recent study has showed that HGF induces macrophages to switch to M2-profile and 
produce IL-10. 38 We also show how implantation of MEECs with injured livers or grafts 
stimulates the production of Th2 cytokines IL-4 and IL-10, and the reduction of the Th1 
cytokines INFγ and IL-2. IL-4 is required for liver regeneration after partial hepatectomy as 
IL-4-deficient mice are associated with massive injury, higher morbidity and mortality and 
impaired liver regeneration.30 The promotion of Th2-derived cytokines in the Th1/th2 
balance explains, in part, the faster and total recovery of liver mass after hepatectomy in 
mice implanted with healthy MEECs. The rescue of dysfunctional endothelium that MEECs 
promote in the ischemic lobe is an additional contribution to the protection and recovery of 
liver mass and reduction of apoptosis.
Embedded endothelial cells constructs can be stored for months, and then placed in 
challenging positions to regulate the local environment. We show that when placed in 
animals that underwent autologous and allogeneic liver grafts MEECs control the local and 
systemic immune response, promote the bridging between recipient liver and graft vessels 
and enhance regeneration. These therapeutic angiogenic, immunomodulatory and anti-
apoptotic effects of MEECs overcome the current risks of stem cell-derived implants for 
transplantation as MEECs restore liver function minimizing any concomitant immune 
reaction. Long-term immunosuppression is required to avoid severe acute and chronic 
rejection and graft loss in transplanted patients.39 We show in immunocompetent mice how 
healthy MEECs can modulate the behavior of host dysfunctional endothelial cells and 
immune system to minimize isograft injury and rejection in the absence of any type of 
immunosuppression. Indeed MEECs reduce the impact of Th1 cytokines and increase Th2 
cytokines in mice receiving isografts improving immunotolerance of implants and isografts. 
Such approach is in line with current strategies aiming to promote stable long-term 
immunological tolerance of the liver graft.39 MEEC rescuing dysfunctional endothelium and 
hepatocyte function after hepatectomy might present a novel treatment of ischemia and 
organ dysfunction in transplantation and suggest a pragmatic solution to the urgent global 
need for liver donations – maximizing efficiency of tissue recovery and reducing risks in 
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donors. This embedded state shields the endothelial cells’ immunogenic surface and reduces 
the expression of MHC-II complex and inflammatory pathways independently of the origin 
of the endothelial cell.40 The immunomodulatory effects of MEECs together with our 
previous knowledge that any source of endothelial cells displays similar benefits when 
implanted after injury,41–42 suggest that the tissue engineering technology presented here 
might be also applied in a human setting. Matrix-embedding commercial primary 
endothelial cells or endothelial cells isolated from vessels harvested during an exploratory 
intervention may be re-implanted to bridge the gap between injured vessels, to stimulate 
angiogenesis, and to improve the success of the engraftment in transplanted patients. 
Possible challenges to take into account for this procedure are the source of these endothelial 
cells (species, tissue compatibility, artery or vein, etc.), the viability of the cells during 
maintenance without adequate CO2 incubators and the risk of contaminations if stored in 
non-sterile areas.
In conclusion, healthy MEECs rescue endothelium function in donor and grafts and also 
exert immunomodulatory effects to stimulate hepatic repair and regeneration and to reduce 
liver graft rejection. Since ischemic injury is a common trait in all of transplants and other 
clinical situations, our outcomes provide insight into potential beneficial use of MEECs in 
liver transplantation and in other ischemia-derived disorders.
Supplementary Material
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Significance of this study
What is already known about this subject?
• Ischemic injury promotes endothelial dysfunction in recipient livers and grafts 
during liver transplantation.
• Liver endothelial cell dysfunction or a failure of mobilization of endothelial 
progenitors impair liver regeneration.
• Recovery of blood perfusion and hepatic mass is critical for recovery of liver 
function in patients undergoing hepatectomy and transplantation.
• Immune reaction of T lymphocytes and macrophages can promote either 
inflammation or regeneration, immunotolerance or graft rejection.
What are the new findings?
• Healthy matrix-embedded endothelial cells rescue dysfunctional endothelium 
from ischemic liver lobes, restoring blood perfusion and reducing apoptosis.
• Healthy matrix-embedded endothelial cells switch the pro-inflammatory 
profile of Th1 and M1 cells to pro-regenerative Th2 and M2 after 
hepatectomy.
• Healthy matrix-embedded endothelial cells bridge injured endothelia of 
recipient and graft livers and protect from inflammatory reaction and rejection 
after engraftment.
• The recovery of endothelium functionality after matrix-embedded endothelial 
cells implantation improves liver regeneration and hepatocyte function after 
hepatectomy and engraftment.
How might it impact on clinical practice in the foreseeable future?
• This investigation defines new strategies to improve the endothelial and 
hepatic function of remnant livers after major resection and liver grafts in 
living donor transplantation.
• Healthy endothelial cells embedded in denatured collagen is a potential 
solution to the current urgent global need for liver donations - maximizing 
efficiency of tissue engraftment and recovery, and reducing risks in donors
• Implantation of matrix-embedded endothelial cells represents a breakthrough 
in the treatment of ischemia and organ dysfunction in transplantation, opens 
new avenues to the management of surgery and intervention in urgent care 
and means a new hope to rescue ischemic organs and tissues.
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Figure 1. 
Beneficial effects of MEECs preventing liver damage in ischemic median lobe after 70% 
hepatectomy. C57BL/6 mice underwent 70% hepatectomy (excision of left lobe and half of 
median lobe). (A) Macroscopic aspect of a pre-op median lobe, 7 days post-op (B) or 7 days 
post-op with acellular denatured collagen implants (Gel) (C) or (D) MEECs. (E) Vascularity 
was analyzed in whole liver by angiography (intracardiac perfusion of FITC-dextran, MW 
2×106 Da) using intravital multiphoton microscopy. Macrophages were also stained by 
intravenous injection of 70 kDa Texas red-dextran 2 hours before angiography and sacrifice. 
Representative images of the vascular network at the interface between the remaining 
median lobe and denatured collagen or MEECs are shown in green; macrophages are shown 
in red and intravascular merge of angiography and Texas red-dextran is shown in yellow. (F) 
Representative images of angiography and quantitative analysis of vascular diameter 
(congestion) and functional number of vessel branches in the hepatic median lobe of sham or 
hepatectomized mice (HP) in the presence or absence of acellular implants (HP+Gel) or 
MEECs (HP+MEECs) 7 days post-op. (G) Gene expression of hepatocyte growth factor 
(HGF) in ischemic median lobe after 3 or 7 days post-op assessed by Real-time PCR (H) To 
detect cell death, the terminal deoxynucleotidyl transferase dUTP nick-end labeling 
(TUNEL) assay was used in median liver lobes from hepatectomized mice in contact with 
acellular implants or MEECs. Representative images of apoptotic nuclei are shown in green. 
Nuclei were stained with DAPI in blue. 200x magnification. Quantification of cell death is 
shown below. (I), Western blot corresponding to active caspase 3 was performed to assess 
apoptosis in median liver lobes from hepatectomized mice in contact with acellular implants 
or MEECs. Representative images of three samples of each group to detect active caspase 3 
and the housekeeping β–actin are plotted. Scale bars, 100 μm. Data are represented as mean 
± s.e.m. **P < 0.01, ***P < 0.001, analysis of variance (ANOVA) or t-student when 
appropriate.
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Figure 2. 
Vascular and immunomodulatory effects of MEECs in contact with ischemic median lobe 
improving liver regeneration and function. C57BL/6 mice underwent 70% hepatectomy 
(excision of left lobe and half of median lobe). (A) Representative images of angiography 
and quantitative analysis of vascular diameter (congestion) and angiogenesis (number of 
anastomoses) in the hepatic right lobe of sham or hepatectomized mice (HP) in the presence 
or absence of acellular implants (HP+Gel) or MEECs (HP+MEECs) 7 days post-op (B) 
Representative images and quantitative analysis of total number of macrophages and 
contacts with vessels in the hepatic right lobe analyzed by injection of 70 kDa Texas red-
dextran 2 hours before sacrifice and angiography (intracardiac perfusion of FITC-dextran, 
MW 2×106 Da) using intravital multiphoton microscopy. Macrophages are shown in red and 
intravascular merge of angiography and Texas red-dextran is shown in yellow. (C) Liver 
restoration rate was assessed in sham or hepatectomized mice in the presence or absence of 
acellular implants or MEECs. Liver restoration rate was calculated as liver weight/body 
weight × 100. (D) Serum markers of liver damage Alanine Aminotransferase (ALT) and 
Aspartate Aminotransferase (AST) were quantified in hepatectomized mice in the presence 
of acellular implants or MEECs. Scale bars, 100 μm. Data are represented as mean ± s.e.m. 
*P < 0.05, **P < 0.01, ***P < 0.001, analysis of variance (ANOVA) or t-student when 
appropriate.
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Figure 3. 
Hepatic immunomodulation of gene expression profiles of macrophages and T helper 
lymphocytes 3 or 7 days after implantation of MEECs. Quantification of M1 (iNOS, COX-2 
and IL1-β) (A) and M2 (Arg1, MRC1 and Retn1a) (B) gene expression profiles by Real-
time PCR in sham or hepatectomized mice in the presence or absence of acellular implants 
(Gel) or MEECs. (C) Quantification of gene expression profiles of Th1 (INFγ and IL-2) and 
(D) Th2 (IL-4 and IL-10) by Real-time PCR in sham or hepatectomized mice in the presence 
or absence of acellular implants (Gel) or MEECs. Data are represented as mean of fold 
change ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, analysis of variance (ANOVA).
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Figure 4. 
Beneficial effects of MEECs preventing liver damage after autologous engraftment. (A) 
Schematic representation of surgical implantation of MEECs or acellular implants in the 
interface between the ischemic median liver lobe and the donated graft from the left liver 
lobe. (B) Macroscopic aspect of median lobe and autologous grafts implanted with acellular 
denatured collagen or (C) MEECs 7 days post-op. (D) Vascularity was analyzed in the 
interface between median liver lobe and autologous graft by angiography using intravital 
multiphoton microscopy. Representative images of the vascular network at the interface 
between the remaining median lobe, acellular Denatured collagen or MEECs and the graft 
are shown in green. (E) Representative images of angiography and quantitative analysis of 
vascular diameter (congestion) and functional number of vessel branches in the hepatic 
median lobe of hepatectomized mice in the presence of acellular implants (HP+Gel) or 
MEECs (HP+MEECs) 7 days post-op. (F) To detect intragraft cell death, TUNEL assay was 
performed in autologous liver grafts in contact with acellular implants or MEECs. 
Representative images of apoptotic nuclei are shown in green. Nuclei were stained with 
DAPI in blue. 200x magnification. Quantification of cell death is shown below. (G) To 
assess apoptosis, Western blot corresponding to active caspase 3 was performed in 
autologous liver grafts from mice in contact with acellular implants or MEECs. 
Representative images of three samples of each group to detect active caspase 3 and the 
housekeeping β–actin are plotted. (H) Serum markers of liver damage Alanine 
Aminotransferase (ALT) and Aspartate Aminotransferase (AST) were quantified in 
hepatectomized mice in the presence of acellular implants or MEECs. Scale bars, 100 μm. 
Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, analysis of 
variance (ANOVA) or t-student when appropriate.
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Figure 5. 
Beneficial effects of MEECs preventing liver damage after allogeneic engraftment. (A) 
Macroscopic aspect of median lobe and allogeneic grafts implanted with acellular denatured 
collagen (Gel) or (B) MEECs 7 days post-op. (C) Vascularity was analyzed in the interface 
between median liver lobe and allogeneic graft by angiography using intravital multiphoton 
microscopy. Representative images of the vascular network at the interface between the 
remaining median lobe, acellular Denatured collagen or MEECs and the graft are shown in 
green. (D) Representative images of angiography and quantitative analysis of vascular 
diameter (congestion) and functional number of vessel branches in the hepatic median lobe 
of hepatectomized mice in the presence of acellular implants (HP+Gel) or MEECs (HP
+MEECs) 7 days post-op. (E) To detect intragraft cell death, TUNEL assay was performed 
in allogeneic liver grafts in contact with acellular implants or MEECs. Representative 
images of apoptotic nuclei are shown in green. Nuclei were stained with DAPI in blue. 200x 
magnification. Quantification of cell death is shown below. (F) To assess apoptosis, Western 
blot corresponding to active caspase 3 was performed in allogeneic liver grafts from mice in 
contact with acellular implants or MEECs. Representative images of three samples of each 
group to detect active caspase 3 and the housekeeping β–actin are plotted. (G) Intragraft 
gene expression profile of immunotolerance expressed as Th1 (INFγ and IL-2) and Th2 
(IL-4 and IL-10) cytokine expression analyzed by Real-Time PCR (H) Serum markers of 
liver damage Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) were 
quantified in mice with isografts in the presence of acellular implants or MEECs. Scale bars, 
100 μm. Data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, 
analysis of variance (ANOVA) or t-student when appropriate.
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